[video=youtube_share;OBRNyNSg2GY]https://youtu.be/OBRNyNSg2GY So I've never posted a video here so forgive me if I'm doing it the wrong way. I made a YouTube video about an alternative therapy to the EpiPen given its recent popularity in the news lately.
As required by AN, there is a link to all nurses in the description and the video itself :)
I'd appreciate any feedback you might have. I know some of you will have some constructive criticism, but please keep it friendly.
I made this video very fast because it's a hot topic right now and I didn't want to miss out. A video will usually take me 2 weeks to edit, gather material, voice over and other stuff. I made this whole video in 5 hours, so I apologize for any mistakes you might find :)
U.S. FDA cited major deficiencies†in an application for a generic version of the EpiPen allergy-reaction injector from Teva Pharmaceutical Industries Ltd., according to a Bloomberg article.
Teva will respond to the FDA, but the company says the launch of its epinephrine injection will be significantly delayed†until at least 2017.
The setback could be good news for Mylan's specialty division, the story said.
And further...how Mylan is going to reap even more profits from the generic auto-injector epi:
[h=2]Why would Mylan do this?[/h]The tactic might help quell a bit of the public furor over rising EpiPen costs.
It could also be a savvy business move.
Last week, Bresch took pains to explain that Mylan actually makes just $274 from each $608 pack of EpiPens it sells, because the product winds through a long line of middlemen before reaching the consumer.
Cutting out the middlemen to sell directly to patients means that Mylan can pocket the full $300 price — and may actually make as much as $26 more on the generic for every unit it sells, depending on the cost of shipping and manufacturing.
Good question, and I am surprised the the "emergency trained nurse practitioner" doesn't know the answer. If you check out the description of the video on YouTube there are other intersting tells.
Anyway, there are several articles on the subject. Here is one:
Rawas-Qalaji, Mutasem et al. (2009). Long-term stability of epinephrine dispensed in unsealed syringes for the first-aid treatment of anaphylaxis. Annals of Allergy, Asthma & Immunology, 102, (6), 500 - 503
Great Video!
Comment - what is the stability of pre drawn epi ( or any drug for that matter) at room temperature?
Specializes in ER, PCU, UCC, Observation medicine.
Good question, and I am surprised the the "emergency trained nurse practitioner" doesn't know the answer. If you check out the description of the video on YouTube there are other intersting tells.
lol You're too much. I never admitted to being God's gift to the world, I don't know it all. If you're saying you know the stability of every single medication you've ever given, which by the way is unnecessary, than you can pat yourself on the back. The video is not a drug guide or fact sheet, just a PSA for one of several alternatives. You're more than welcome to make your own video for the world to criticize.
Am unsure why there is so much snark coming out of this thread....this is an acceptable alternative. One which is gaining popularity as even with the generic, which is currently stalled in production, costing approx 300.
traumaRUs, MSN, APRN
87 Articles; 21,287 Posts
And generic auto-injector epi has been delayed:
U.S. FDA cited major deficiencies†in an application for a generic version of the EpiPen allergy-reaction injector from Teva Pharmaceutical Industries Ltd., according to a Bloomberg article.
Teva will respond to the FDA, but the company says the launch of its epinephrine injection will be significantly delayed†until at least 2017.
The setback could be good news for Mylan's specialty division, the story said.
And further...how Mylan is going to reap even more profits from the generic auto-injector epi:
[h=2]Why would Mylan do this?[/h]The tactic might help quell a bit of the public furor over rising EpiPen costs.
It could also be a savvy business move.
Last week, Bresch took pains to explain that Mylan actually makes just $274 from each $608 pack of EpiPens it sells, because the product winds through a long line of middlemen before reaching the consumer.
Cutting out the middlemen to sell directly to patients means that Mylan can pocket the full $300 price — and may actually make as much as $26 more on the generic for every unit it sells, depending on the cost of shipping and manufacturing.